Related Experiment Video
Updated: May 1, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.4K
Biosimilars for chronic plaque psoriasis: a 2026 update.
Martina Maurelli1, Andrea Danese1, Paolo Gisondi1
1Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Expert Review of Clinical Pharmacology
|April 29, 2026
Summary
Biosimilars offer a cost-effective way to increase access to biologic treatments for moderate-to-severe psoriasis. Evidence shows they are as effective and safe as reference biologics, supporting their use as first-line options.
Area of Science:
- Dermatology
- Pharmacoeconomics
- Biotechnology
Background:
- Biologic therapies are crucial for moderate-to-severe psoriasis but face challenges with cost and accessibility.
- Biosimilars represent a strategy to overcome these limitations and improve patient access.
Purpose of the Study:
- To review current evidence on approved psoriasis biosimilars, including efficacy, safety, interchangeability, and economic impact.
- To assess the role of biosimilars in improving access to biologic treatments for psoriasis.
Main Methods:
- Narrative review of literature published between January 2015 and January 2026.
- Searches conducted in PubMed/MEDLINE and Embase for clinical trials, real-world studies, and pharmacoeconomic analyses.
Main Results:
- Biosimilars demonstrated high similarity to reference biologics with no clinically meaningful differences in efficacy, safety, or immunogenicity.
- Pharmacoeconomic studies confirmed significant cost savings and reduced cost-per-responder rates.
- Evidence supports broader and earlier access to biologic therapy through biosimilar utilization.
Conclusions:
- Biosimilars are effective, safe, and cost-saving alternatives to reference biologics for psoriasis.
- Consideration of biosimilars as first-line biologic options can improve treatment access and health system sustainability.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:22iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97